Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Coronary Occlusion

ClinicalTrials.gov lists 66 trials for Coronary Occlusion or a narrower condition beneath it. Abbott Medical Devices has the most among industry and government lead sponsors, with 5.

MeSH D054059 Cardiovascular Diseases C14
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 2 Phase 2 Phase 2 2 Phase 3 Phase 3 5 Phase 4 Phase 4 5 Not applicable Not applicable 28 Observational Observational 24 Phase 1 Phase 1 2 Phase 2 Phase 2 2 Phase 3 Phase 3 5 Phase 4 Phase 4 5 Not applicable Not applicable 28 Observational Observational 24

Trials per phase

66 of the 66 trials are tagged with Coronary Occlusion itself; the rest are tagged with a narrower condition beneath it.

Get the Coronary Occlusion report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Coronary Occlusion trials start? (22)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 6

2002: 1 trials (Phase 3 1) 2005: 1 trials (Phase 3 1) 2006: 2 trials (Phase 4 1, Phase 1 1) 2007: 4 trials (Observational 1, Not applicable 2, Phase 2 1) 2008: 3 trials (Observational 1, Phase 3 2) 2009: 2 trials (Phase 4 2) 2010: 3 trials (Observational 1, Not applicable 1, Phase 4 1) 2011: 3 trials (Observational 1, Not applicable 2) 2012: 1 trials (Observational 1) 2013: 4 trials (Observational 2, Not applicable 2) 2015: 2 trials (Not applicable 2) 2016: 4 trials (Observational 1, Not applicable 3) 2017: 4 trials (Observational 2, Not applicable 2) 2018: 4 trials (Observational 2, Not applicable 2) 2019: 2 trials (Observational 1, Not applicable 1) 2020: 5 trials (Observational 3, Not applicable 1, Phase 1 1) 2021: 6 trials (Observational 1, Not applicable 5) 2022: 1 trials (Not applicable 1) 2023: 3 trials (Observational 1, Not applicable 2) 2024: 4 trials (Observational 2, Phase 3 1, Phase 2 1) 2025: 4 trials (Observational 3, Not applicable 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 2
2025 4
2024 4
2023 3
2022 1
2021 6
2020 5
2019 2
2018 4
2017 4

No forecast is made for this condition: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Coronary Occlusion trials in? (6)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 2
Phase 2 2
Phase 3 5
Phase 4 5
Not applicable 28
Observational 24

How many Coronary Occlusion trials are recruiting? (7)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 1
Recruiting 7
Active, not recruiting 6
Completed 34
Suspended 1

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Coronary Occlusion trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Abbott Medical Devices 5
AusculSciences Canada Inc. 2
Nitiloop Ltd. 2
Anesiva, Inc. 1
Angel Medical Systems 1

Which drugs are being tested for Coronary Occlusion? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
edifoligide (E2F Decoy) 1
EPOETIN ALFA 1

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Liberal blood pressure management 1
Catheter-based intracoronary injection 1
aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor 1
Thoracic Epidural Analgesia 1
Blood Transfusion 1

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Coronary Occlusion trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Coronary artery stenosis 147 3
Angina pectoris 139 4
In hospital mortality 110 1
Coronary artery restenosis 61 4
Death 60 4

Which publications cover Coronary Occlusion? (309)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Early vs Late Staged PCI After Subintimal Tracking and Re-Entry for Chronic Total Occlusions: A Randomized Trial. Journal of the American College of Cardiology 2026 Yes
Chronic total occlusions and coronary artery bypass grafting outcomes. The Journal of thoracic and cardiovascular surgery 2025 Yes
Validation of the coronary artery specific chronic total occlusion percutaneous coronary intervention angiographic difficulty scores in the PROGRESS-CTO registry. Cardiovascular revascularization medicine : including molecular interventions 2025 Yes
Use of the Ostial Flash balloon in aorto-ostial chronic total occlusion percutaneous coronary intervention. The Journal of invasive cardiology 2025 Yes
Vascular Healing After Biodegradable Polymer Sirolimus-Eluting Versus Durable Polymer Everolimus-Eluting Stents in Chronic Total Occlusions. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2025 Yes

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages